News and Announcements
DroneShield (ASX: DRO) releases RfPatrol and first customer order places
- Published May 02, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX Release
Release of RfPatrol, First Customer Order Placed
DroneShield Ltd (ASX: DRO) (“DroneShield” or the “Company”) is pleased to announce the release of body-wrong drone detection product RfPatrol. Weighing under 1kg, the product is expected to be of significant interest to a range of DroneShield’s customer base globally, across military, law enforcement, security and VIP markets. Importantly, as RfPatrol is a completely passive (non-emitting) product, it substantially broadens the range of customers to whom the product is lawfully available. The product was developed in response to substantial customer interest.
DroneSHielf is also pleased to announce an immediate customer purchase order for a small quantity of RfPatrol units by the Department of Defence of a Western country. While the revenue from the order is not material, the order for evaluation towards a potential larger purchase order.
Read the full ASX announcement here.
About DroneShield (ASX: DRO)
Based in Sydney (Australia), Virginia and Washington DC (USA) and London (UK), DroneShield is a worldwide leader in drone security technology. The Company has developed pre-eminent drone security solutions that protect people, organisations and critical infrastructure from intrusion from drones. Its leadership brings world-class expertise in engineering and physics, combined with deep experience in defence, intelligence, and aerospace.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
